Janux Therapeutics, Inc. (NASDAQ:JANX) Major Shareholder Ventures Xi L.P. Avalon Sells 158,031 Shares

Janux Therapeutics, Inc. (NASDAQ:JANX) major shareholder Ventures Xi L.P. Avalon sold 158,031 shares of Janux Therapeutics stock in a transaction on Thursday, September 12th. The shares were sold at an average price of $47.00, for a total value of $7,427,457.00. Following the completion of the transaction, the insider now owns 2,959,175 shares in the company, valued at approximately $139,081,225. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Large shareholders that own at least 10% of a company’s shares are required to disclose their transactions with the SEC.

Ventures Xi L.P. Avalon also recently made the following trade(s):

• On Friday, September 6th, Ventures Xi L.P. Avalon sold 108,365 shares of Janux Therapeutics stock. The stock was sold at an average price of $42.00, for a total value of $4,551,330.00.
• On Monday, September 9th, Ventures Xi L.P. Avalon sold 2,182 shares of Janux Therapeutics stock. The stock was sold at an average price of $42.33, for a total transaction of $92,364.06.

Janux Therapeutics Stock Performance

NASDAQ:JANX opened at $50.01 on Friday. Janux Therapeutics, Inc. has a one year low of $5.65 and a one year high of $65.60. The business’s 50-day simple moving average is $42.78 and its 200 day simple moving average is $44.15. The stock has a market cap of $2.61 billion, a price-to-earnings ratio of -40.99 and a beta of 3.57.

Janux Therapeutics (NASDAQ:JANX) last released its earnings results on Wednesday, August 7th. The company reported ($0.11) EPS for the quarter, beating the consensus estimate of ($0.31) by $0.20. The company had revenue of $8.90 million during the quarter, compared to analysts’ expectations of $0.77 million. Janux Therapeutics had a negative return on equity of 8.78% and a negative net margin of 291.17%. Janux Therapeutics’s revenue for the quarter was up 709.1% on a year-over-year basis. On average, equities research analysts predict that Janux Therapeutics, Inc. will post -1.18 EPS for the current year.

Institutional Investors Weigh In On Janux Therapeutics

Institutional investors have recently modified their holdings of the stock. Amalgamated Bank raised its position in shares of Janux Therapeutics by 61.1% during the 2nd quarter. Amalgamated Bank now owns 970 shares of the company’s stock valued at $41,000 after acquiring an additional 368 shares in the last quarter. Summit Securities Group LLC bought a new stake in Janux Therapeutics during the second quarter valued at $29,000. Plato Investment Management Ltd acquired a new stake in shares of Janux Therapeutics during the second quarter worth $42,000. Zurcher Kantonalbank Zurich Cantonalbank bought a new position in shares of Janux Therapeutics in the 2nd quarter worth about $151,000. Finally, Quest Partners LLC boosted its holdings in shares of Janux Therapeutics by 307.2% in the 2nd quarter. Quest Partners LLC now owns 5,795 shares of the company’s stock valued at $243,000 after buying an additional 4,372 shares during the period. Institutional investors and hedge funds own 75.39% of the company’s stock.

Analyst Ratings Changes

Several equities research analysts have issued reports on JANX shares. HC Wainwright reiterated a “buy” rating and set a $63.00 price objective on shares of Janux Therapeutics in a research note on Monday, August 19th. Scotiabank decreased their price target on shares of Janux Therapeutics from $47.00 to $42.00 and set a “sector perform” rating for the company in a research report on Friday, August 9th. Cantor Fitzgerald reissued an “overweight” rating and issued a $100.00 price objective on shares of Janux Therapeutics in a research report on Thursday, August 8th. Wedbush reaffirmed an “outperform” rating and issued a $74.00 target price on shares of Janux Therapeutics in a research report on Thursday, August 8th. Finally, Stifel Nicolaus started coverage on Janux Therapeutics in a report on Friday, September 6th. They set a “buy” rating and a $70.00 target price on the stock. One investment analyst has rated the stock with a hold rating and eight have issued a buy rating to the company. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $66.13.

Janux Therapeutics Company Profile

Janux Therapeutics, Inc, a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma.